Evidence map›Paper›PMID 37296351›Full record

ArticleJournal of epidemiology and global health2023

Effect of Broad-Spectrum Antibiotic De-escalation on Critically Ill Patient Outcomes: A Retrospective Cohort Study.

Namareq Aldardeer, Ismael Qushmaq, Bashayer AlShehail, Nadia Ismail, Abrar AlHameed, Nader Damfu, Mohammad Al Musawa, Renad Nadhreen, Bayader Kalkatawi, Bashaer Saber and 5 more

Abstract read
In one paragraph

Article in Journal of epidemiology and global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Simplified Spectrum Score (SScientific reports · 2024
    Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Namareq AldardeerPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, MBC J-11, P.O. Box 40047, Jeddah, 21499, Saudi Arabia. aldardeern@hotmail.com.ORCID 0000-0001-9323-1606
Ismael QushmaqSection of Critical Care Medicine, Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Bashayer AlShehailPharmacy Practice Department, College of Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Nadia IsmailPharmaceutical Care Division, King Fahad Hospital of the University, Al-Khobar, Saudi Arabia.
Abrar AlHameedPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Madinah, Saudi Arabia.
Nader DamfuInfection Prevention and Control Department, King Abdul Aziz Medical City, Jeddah, Saudi Arabia.
Mohammad Al MusawaPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, MBC J-11, P.O. Box 40047, Jeddah, 21499, Saudi Arabia.
Renad NadhreenSection of Critical Care Medicine, Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Bayader KalkatawiPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, MBC J-11, P.O. Box 40047, Jeddah, 21499, Saudi Arabia.
Bashaer SaberPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, MBC J-11, P.O. Box 40047, Jeddah, 21499, Saudi Arabia.
Mohannad NasserPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, MBC J-11, P.O. Box 40047, Jeddah, 21499, Saudi Arabia.
Aiman RamdanFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Abrar ThabitPharmacy Practice Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Mohammed AldhaeefiDepartment of Clinical and Administrative Pharmacy Sciences, College of Pharmacy, Howard University, Washington, DC, USA.
Abeer Al ShukairiDepartment of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAntibiotic de-escalation (ADE) in critically ill patients is controversial. Previous studies mainly focused on mortality; however, data are lacking about superinfection. Therefore, we aimed to identify the impact of ADE versus continuation of therapy on superinfections rate and other outcomes in critically ill patients.

methodsThis was a two-center retrospective cohort study of adults initiated on broad-spectrum antibiotics in the intensive care unit (ICU) for ≥ 48 h. The primary outcome was the superinfection rate. Secondary outcomes included 30-day infection recurrence, ICU and hospital length of stay, and mortality.

results250 patients were included, 125 in each group (ADE group and continuation group). Broad spectrum antibiotic discontinuation occurred at a mean of 7.2 ± 5.2 days in the ADE arm vs. 10.3 ± 7.7 in the continuation arm (P value = 0.001). Superinfection was numerically lower in the ADE group (6.4% vs. 10.4%; P = 0.254), but the difference was not significant. Additionally, the ADE group had shorter days to infection recurrence (P = 0.045) but a longer hospital stay (26 (14-46) vs. 21 (10-36) days; P = 0.016) and a longer ICU stay (14 (6-23) vs. 8 (4-16) days; P = 0.002).

conclusionNo significant differences were found in superinfection rates among ICU patients whose broad-spectrum antibiotics were de-escalated versus patients whose antibiotics were continued. Future research into the association between rapid diagnostics with antibiotic de-escalation in the setting of high resistance is warranted.

Indexed as

Anti-Bacterial AgentsSuperinfectionAdultCritical IllnessHumansIntensive Care UnitsRetrospective StudiesAnti-Bacterial AgentsAntibioticsBroad spectrumDe-escalationStewardshipSuperinfection

Identifiers

PMID37296351
PMCPMC10255942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.